GSA Capital Partners LLP Takes $1.25 Million Position in Gilead Sciences, Inc. $GILD

GSA Capital Partners LLP bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, Holdings Channel reports. The firm bought 9,877 shares of the biopharmaceutical company’s stock, valued at approximately $1,248,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Paulson Wealth Management Inc. lifted its position in Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 67 shares in the last quarter. Essex Financial Services Inc. increased its position in shares of Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares in the last quarter. Davidson Trust Co. raised its stake in shares of Gilead Sciences by 4.1% in the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 74 shares during the period. Alpha Cubed Investments LLC raised its stake in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares during the period. Finally, Financial Connections Group Inc. lifted its holdings in shares of Gilead Sciences by 30.2% during the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 76 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.4%

GILD stock opened at $138.92 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $172.25 billion, a P/E ratio of -52.03 and a beta of 0.32. The firm has a 50 day simple moving average of $130.33 and a 200-day simple moving average of $136.43.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.01 earnings per share. On average, equities research analysts predict that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. Gilead Sciences’s payout ratio is presently -122.85%.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the transaction, the insider owned 124,234 shares of the company’s stock, valued at $15,395,077.28. This trade represents a 2.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 51,000 shares of company stock valued at $6,568,860. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on GILD shares. Weiss Ratings cut shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Needham & Company LLC reissued a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Royal Bank Of Canada upped their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday. Twenty-four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.